QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.

Press

1Dec 2025

Strengthening ERS expertise – welcome Ankit!

We’re excited to welcome Ankit Gupta to the Quantify team as an Assistant Manager in our Evidence Review & Synthesis (ERS) function.

Ankit brings valuable experience from his previous role at Lumanity as a Senior Research Associate. With a Master’s in Medicinal & Pharmaceutical Chemistry and a Bachelor’s in Pharmacy, he’s well-equipped to support our work in systematic literature reviews (SLR), targeted literature reviews (TLR), and more.

We’re thrilled to have […]

29Nov 2025

📊Momentum for EHDS in Sweden

Last week, Quantify’s Head of RWE and Analytics Emilie Toresson Grip were invited to join 70+ leaders from healthcare, academia, and industry to the Swelife High-Level Meeting. The meeting aimed to discuss concrete solutions to health data challenges in Sweden in the light of EHDS adoption and implementation regarding secondary use of data, including suggestions to improve availability of large volumes of harmonized health data.

While there are many challenges ahead, it […]

28Nov 2025

🌅Quiet mornings, clear purpose

On her way into the office, one of our colleagues captured this view: Stockholm at dawn, river reflections, lights still glowing.

A calm start to a busy week.

At Quantify Research, clarity often comes in quiet moments.

Behind every analysis is intent. Behind every dataset, a patient story. Behind every Monday, a new opportunity to do meaningful work.

Here’s to beginning the week with focus, curiosity, and a steady hand—
helping to improve patients’ […]

14Nov 2025

Real‑World Diabetes Insights

🩺 Real‑world diabetes research—done right
From risk prediction in metabolic syndrome to cost comparisons in insulin delivery, diabetes care needs rigour, relevance, and real‑world insight.

🔹 In 2024, we helped show how metabolic syndrome traits raise the risk of liver outcomes in Type 2 diabetes: Read here
🔹 In 2022, we analysed Nordic RWE showing empagliflozin’s impact on cardiorenal outcomes and mortality in Sweden: Read here
🔹 In 2019, we assessed […]